# Synthgene Biotechnology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/synthgene-biotechnology-co

- Industry: Biotechnology
- Headquarters: Wuxi, China
- Website: www.syngenebio.com
- Total disclosed funding: $47M
- Latest round: Series B (Mar 27, 2025)
- Investors on record: 8

## About

Based in Wuxi, China and established in 2018, Synthgene Biotechnology Co., Ltd. operates as a biotech company that focuses on the development of core materials for immunodiagnostic and in vitro diagnostic reagents and instruments. The core team members come from Nanjing University. The company has been selected as the Nanjing cultivates unicorn company. In March 2026, the firm clsoed a round of venture funding.

The products developed by the company can be categorized into eight parts, which are mRNA Raw Material, Sugars, GalNAc, Phosphonamidites, Nucleosides, Molecular Diagnostic, Succinates, and Phosphorus reagent. The specified products include Cap analogs, dNTPs, LNA, etc.

The company generates revenue by developing nucleosides, nucleotides, diagnostic antigens, and antibodies.

## Funding rounds

- Series B, Mar 27, 2025 — Leader Venture Capital
- Series A, Apr 11, 2022, $47M — Legend Star, LYFE Capital, Sherpa Healthcare Partners, Lake Bleu Capital
- Series A, Jun 30, 2021 — Jolmo Capital, Dynamic Capital, Yingdi Capital

## Investors

- Jolmo Capital (https://capitalatlas.ai/funds/jolmo-capital) — Series A
- Dynamic Capital (https://capitalatlas.ai/funds/dynamic-capital) — Series A
- Yingdi Capital — Series A
- Legend Star (https://capitalatlas.ai/funds/legend-star) — Series A
- LYFE Capital — Series A
- Sherpa Healthcare Partners (https://capitalatlas.ai/funds/sherpa-healthcare-partners) — Series A
- Lake Bleu Capital (https://capitalatlas.ai/funds/lake-bleu-capital) — Series A
- Leader Venture Capital (https://capitalatlas.ai/funds/leader-venture-capital) — Series B